Introduction
The treatment of nasal polyps usually combines anti-inflammatory medicines, procedures to shrink or remove the growths, and long-term control of the conditions that drive them. Nasal polyps are soft, benign swellings of the lining of the nose and sinuses that arise when chronic inflammation causes the tissue to become edematous and overgrow. Because the problem is rooted in persistent mucosal inflammation and impaired drainage within the sinus passages, treatment is aimed not only at reducing visible polyp tissue but also at calming the inflammatory processes that allow polyps to form and recur.
Therapy is chosen to reduce obstruction, improve airflow and sinus drainage, restore smell when possible, and decrease the chance of repeated infections or recurrent polyp growth. Some treatments act by suppressing inflammatory signaling in the mucosa, while others mechanically remove obstructing tissue or reduce swelling enough to reopen the sinus passages. In many cases, nasal polyps are managed as a chronic inflammatory disorder rather than a one-time structural problem.
Understanding the Treatment Goals
The main goals of treatment are to reduce the size of the polyps, relieve nasal blockage, improve sense of smell, decrease mucus accumulation, and prevent repeated inflammation of the sinus lining. These goals reflect the biology of the condition. Polyps form when the mucosa stays inflamed over time, becomes fluid-rich, and expands into protruding lesions that can block the nasal cavity and sinus openings. Treating the polyps therefore means treating the inflammatory environment that supports them.
A second goal is to restore normal sinus function. The sinuses depend on open drainage pathways and coordinated movement of mucus by cilia. When polyps obstruct these channels, mucus becomes trapped, pressure can build, and infections become more likely. Treatments are selected to reopen these pathways or limit the inflammatory swelling that closes them. In severe or recurrent disease, another goal is to reduce the frequency of relapse, since nasal polyps often return if the underlying inflammatory process remains active.
Common Medical Treatments
Intranasal corticosteroids are the most commonly used long-term medical treatment. These are steroid sprays, and sometimes steroid drops or irrigations, placed directly into the nasal cavity. They reduce the production of inflammatory mediators, decrease local immune-cell activity, and limit the edema that gives polyps their soft, swollen character. By reducing mucosal inflammation, they can shrink existing polyps and slow new growth. Their primary target is the inflamed nasal lining rather than the polyp tissue alone.
Short courses of oral corticosteroids are used when inflammation is more severe or rapid reduction in swelling is needed. Systemic steroids reach the entire upper airway and strongly suppress inflammatory signaling, which can produce a faster decrease in polyp size than topical treatment. This works by reducing capillary permeability, tissue edema, and inflammatory cell activation. The effect can be substantial, but it is usually temporary if the inflammatory process continues after the course ends.
Saline irrigation is often used alongside medication. This involves flushing the nasal passages with saline solution. Mechanically, it helps clear thick mucus, inflammatory debris, and crusting, which improves contact between topical medicines and the mucosal surface. Physiologically, irrigation can support mucociliary clearance by thinning secretions and reducing the stagnant environment that favors persistent inflammation and infection.
Antihistamines and leukotriene modifiers may be used in selected patients, especially when allergy or aspirin-related airway disease contributes to symptoms. Antihistamines block histamine signaling, which can reduce allergic mucosal swelling and mucus production. Leukotriene modifiers interfere with leukotriene-mediated inflammation and bronchial or nasal congestion. These treatments do not directly remove polyps, but they can reduce the inflammatory signals that feed the disease process in susceptible individuals.
Biologic therapies are used in some patients with severe, recurrent nasal polyps, particularly when disease is associated with type 2 inflammation, asthma, or aspirin-exacerbated respiratory disease. These agents target specific immune pathways, such as interleukin-4, interleukin-13, or immunoglobulin E-related signaling, depending on the drug. By blocking key cytokine pathways that drive eosinophilic inflammation, mucus overproduction, and tissue swelling, biologics reduce polyp burden and improve nasal airflow in patients whose disease is linked to persistent immune activation.
Antibiotics are not primary treatment for nasal polyps themselves, because polyps are not caused by bacterial infection. They may be used if there is a concurrent bacterial sinus infection. In that setting, the purpose is to treat the infection and reduce additional inflammatory stress on the already swollen sinus mucosa, not to directly treat the polyp tissue.
Procedures or Interventions
Endoscopic sinus surgery is the main procedure used when medical treatment does not adequately control symptoms, when polyps cause substantial blockage, or when recurrent sinus infections occur because the drainage pathways remain obstructed. The procedure is performed through the nostrils using an endoscope and specialized instruments. The surgeon removes polyp tissue and may enlarge the natural sinus openings. This changes the structure of the nasal and sinus passages by improving ventilation, restoring mucus drainage, and creating space for topical therapies to reach the mucosa more effectively.
Surgery does not cure the inflammatory tendency that caused the polyps, but it reduces the burden of obstructive tissue and corrects the anatomical consequences of long-standing inflammation. After surgery, the sinus cavities are usually less congested and more accessible to steroid sprays or irrigations, which is one reason medical therapy is still needed afterward in many patients.
In certain cases, debulking procedures or targeted removal of particularly large polyps may be used to relieve severe obstruction more quickly. These approaches reduce physical blockage and improve airflow, but they do not eliminate the underlying immune-driven mucosal disease. For that reason, they are typically part of a broader treatment plan rather than a stand-alone solution.
Supportive or Long-Term Management Approaches
Long-term management focuses on keeping inflammation under control and limiting the conditions that allow polyps to recur. Ongoing use of topical nasal corticosteroids is common because these medications maintain local suppression of inflammatory activity in the mucosa. Over time, they help preserve the reduced tissue swelling achieved by other treatments and lower the probability that new polyps will form from chronically inflamed lining tissue.
Regular saline irrigation is another supportive measure because it helps maintain clearance of mucus and inflammatory material. By reducing retained secretions, it lowers the local inflammatory burden and supports better function of the ciliated epithelium. This is especially relevant in chronic sinus disease, where thick mucus and stagnant airflow contribute to ongoing mucosal irritation.
Monitoring and follow-up care are central to long-term control. Nasal polyps can recur because the underlying inflammatory state may persist even after surgery or medication-induced shrinkage. Follow-up allows assessment of whether the mucosa remains swollen, whether airflow and smell are improving, and whether the current therapy is adequately suppressing the disease process. In people with related inflammatory disorders such as asthma or aspirin sensitivity, management of those conditions also influences the nasal disease, because the airway inflammation often extends beyond the nose alone.
Factors That Influence Treatment Choices
Treatment varies according to the severity and extent of disease. Small polyps with mild symptoms may respond to topical corticosteroids and irrigation, whereas extensive polyposis causing severe obstruction often requires stronger anti-inflammatory therapy, biologics, or surgery. The stage of the condition matters because early inflammatory swelling may still be reversible with medication, while long-standing disease can create more persistent tissue remodeling and obstruction.
Age and general health also influence treatment decisions. Some therapies are better suited to individuals who can tolerate systemic medication or procedures, while others are preferred when limiting systemic exposure is important. Related conditions are especially relevant. Asthma, allergic rhinitis, aspirin-exacerbated respiratory disease, and chronic rhinosinusitis often coexist with nasal polyps and reflect overlapping inflammatory pathways. When those conditions are present, treatment may need to address a broader airway-inflammatory pattern rather than isolated nasal symptoms.
Response to previous therapy is another major factor. If topical steroids have reduced symptoms only partially, clinicians may add a short course of oral steroids, consider biologic therapy, or recommend surgery if obstruction remains severe. If polyps recur after surgery, that usually indicates that the inflammatory drive is still active, so treatment often shifts toward more sustained medical control rather than repeated structural removal alone.
Potential Risks or Limitations of Treatment
Medical treatments have limitations because they control inflammation rather than permanently reversing the biologic tendency to form polyps. Intranasal corticosteroids are generally well tolerated, but they may cause local irritation, dryness, or nosebleeds because chronic steroid exposure can thin the mucosa in some patients. Oral corticosteroids are more powerful but carry greater systemic risks, including effects on glucose metabolism, bone turnover, mood, and immune function, which is why they are usually used briefly.
Biologic therapies are targeted, but they are not universal solutions. They may be costly, require repeated dosing, and do not work equally well in every inflammatory subtype. Their benefit depends on whether the disease is driven by the pathways the drug is designed to block. Antibiotics have little effect on the polyps themselves unless a true bacterial infection is present, so they cannot address the central inflammatory mechanism of the condition.
Procedures also have limitations. Surgery can reopen blocked passages and remove diseased tissue, but the mucosal inflammation can persist or recur, allowing polyps to return. Surgical risks arise from the anatomy of the sinuses, which are close to the eyes, skull base, and major blood vessels. Potential complications include bleeding, infection, scarring, or injury to nearby structures, although these are uncommon when performed appropriately. Because surgery modifies structure rather than the inflammatory drive alone, postoperative medical treatment is usually needed to preserve the benefit.
Conclusion
Nasal polyps are treated by combining anti-inflammatory medication, selected procedures, and long-term disease control. The central biological problem is chronic inflammation of the nasal and sinus mucosa, which causes tissue edema, mucosal overgrowth, and obstruction of drainage pathways. Treatments work by suppressing that inflammation, reducing tissue swelling, restoring airflow and mucus clearance, or physically removing obstructive polyp tissue.
Intranasal corticosteroids, saline irrigation, systemic steroids, biologics, and surgery each act at different points in the disease process. Some reduce immune activity in the mucosa, some improve the physical environment of the nose and sinuses, and some remove the structural consequences of prolonged inflammation. Because nasal polyps often arise from ongoing inflammatory disease, effective treatment usually aims not only at short-term symptom relief but also at preventing recurrence and preserving normal sinonasal function over time.